샘플 요청 목록

 카트 문의
시장보고서
상품코드
1750776

eClinical 솔루션 시장 규모, 점유율, 동향 분석 리포트 : 제품별, 전달 모드별, 개발 단계별, 최종 용도별, 지역별, 부문 예측(2025-2030년)

eClinical Solutions Market Size, Share & Trends Analysis Report By Product (eCOA, CTMS), By Delivery Mode (Web And Cloud Based, On-premise), By Development Phase, By End Use (CRO, Academic Institutes), By Region, And Segment Forecasts, 2025 - 2030
발행일: | 리서치사: Grand View Research | 페이지 정보: 영문 198 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

eClinical 솔루션 시장의 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 eClinical 솔루션 시장 규모는 2030년까지 227억 4,000만 달러에 달할 것으로 예측됩니다.

이 시장은 2025-2030년 연평균 복합 성장률(CAGR) 14.39%를 보일 것으로 예측됩니다. 바이오 제약 및 제약 기업의 연구개발 활동 증가, 임상시험에 소프트웨어 솔루션 적용, 고객 기반 확대가 시장 성장을 가속할 것으로 예상되며, COVID-19 기간 중 임상 실험실에서 COVID-19 검사에 대한 높은 수요가 발생했습니다. 임상 데이터 관리 시스템은 이러한 검사 시설이 매일 대량으로 유입되는 검체를 원활하게 관리할 수 있도록 돕고 있습니다. 전자 데이터 캡처 및 Wi-Fi 연결과 같은 기술 발전은 향후 수년간 시장을 주도할 것으로 예측됩니다.

임상 데이터 추적 및 분석에 대한 수요가 증가함에 따라 효과적인 임상 솔루션에 대한 필요성이 증가하고 있습니다. 효율적인 임상 개발 프로세스 관리에 대한 미충족 수요는 예측 기간 중 시장 성장을 가속할 것으로 예측됩니다. 또한 임상시험 분야의 디지털 혁신과 데이터 중심 접근 방식에 대한 선호는 시장을 크게 촉진하고 있으며, 전자임상 솔루션은 중복 데이터 입력을 없애고 현장 검증 및 소스 데이터 확인을 줄여 비용을 최적화하고 단일 정보 소스를 제공함으로써 시장을 촉진하고 있습니다. 이러한 장점에 대한 인식이 높아짐에 따라 시장을 촉진할 것으로 예측됩니다.

임상시험에서 e-임상 워크플로우의 채택이 증가하고 있으며, 임상 개발 프로세스에 큰 잠재력을 가져다주고 있습니다. 이러한 솔루션은 개발의 각 단계에서 의사결정을 용이하게 합니다. 원활한 설계를 활용하고 실패한 화합물을 식별하여 개발 단계의 비용과 시간을 절감할 수 있습니다. 데이터 및 환자 안전 정보에 대한 빠른 액세스를 제공하여 신속한 의사결정을 지원합니다. 2023년 8월, Sitero는 임상시험 제공을 강화하기 위해 Clarios eClinical의 기술 제품군을 인수하여 임상시험 제공을 강화했습니다. 이번 인수는 혁신의 최전선에 서서 고객에게 최고의 지원과 서비스를 제공하겠다는 Sitero의 헌신을 보여주는 것입니다.

e-클리니컬 솔루션 시장 보고서 하이라이트

  • 제품별로는 CTMS 분야가 2024년 시장을 주도하며 약 20.2%의 매출 점유율을 차지헸습니다. 이는 임상시험 활동의 엔드 투 엔드 중앙 집중식 관리, 수작업 프로세스에 대한 의존성 제거, 실시간 상태 추적, 여러 데이터베이스의 유지 관리 등의 이점이 있으며, 이는 종합적으로 임상시험의 전반적인 효율성을 향상시키기 때문입니다.
  • 웹 및 클라우드 기반 시스템은 유연성, 높은 접근성, 무시할 수 있는 처리 비용, 손쉬운 데이터 백업과 같은 통합 기능으로 인해 예측 기간 중 비약적인 CAGR을 보일 것으로 예측됩니다. 이러한 시스템을 통해 실시간 데이터를 얻을 수 있으므로 사용자는 신속한 의사결정을 내릴 수 있으며, 위험 기반 모니터링에 양질의 정보를 제공할 수 있습니다.
  • 개발 단계별로 보면 2024년 3단계 부문이 53.3%의 가장 큰 시장 점유율을 차지헸습니다. 1단계 부문은 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다.
  • 최종 용도별로는 CRO 부문이 2024년 가장 큰 매출 점유율을 차지했습니다. 이 부문은 제약 회사의 전반적인 지출을 줄이려는 경향이 증가함에 따라 예측 기간 중 눈에 띄는 CAGR로 상승할 것으로 예측됩니다.

목차

제1장 eClinical 솔루션 시장 : 조사 방법과 범위

제2장 eClinical 솔루션 시장 : 개요

  • 시장 전망
  • 부문 전망

제3장 eClinical 솔루션 시장 : 변수, 동향, 범위

  • 보조 시장 분석
  • 가격 분석
  • 사용자/구입자의 인식 분석
  • 테크놀러지의 개요
  • 규제의 개요
  • 시장 역학
  • 업계 분석 - Porter의 산업 분석
  • eClinical 솔루션 시장 - SWOT 분석 : 요인별(정치·법률, 경제, 사회, 기술)
  • COVID-19의 영향 분석

제4장 eClinical 솔루션 시장 : 제품 분석

  • 제품 비즈니스 분석

제5장 eClinical 솔루션 시장 : 전달 모드 분석

  • 전달 모드 비즈니스 분석

제6장 eClinical 솔루션 시장 : 개발 단계 분석

  • 개발 단계 비즈니스 분석

제7장 eClinical 솔루션 시장 : 최종 용도 분석

  • 최종 용도 비즈니스 분석

제8장 eClinical 솔루션 시장 : 지역별 시장 분석, 제품별, 전달 모드별, 개발 단계별, 최종 용도별, 2018-2030년

  • 지역별 시장 점유율 분석, 2024년·2030년
  • 지역 시장 스냅숏
  • 북미
  • 유럽
  • 아시아태평양
  • 중남미
  • 중동 및 아프리카

제9장 eClinical 솔루션 시장 : 경쟁 구도

  • 참가자 개요
  • 기업의 시장 현황 분석
  • 기업 분류
  • 전략 지도제작
  • 기업 개요/상장기업

제10장 KOL 제안/결론

제11장 조사 인사이트/사용 사례

KSA 25.06.25

eClinical Solutions Market Growth & Trends:

The global eClinical solutions market size is anticipated to reach USD 22.74 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 14.39% from 2025 to 2030. Increasing R&D activities by biopharma and pharma companies, application of software solutions in clinical trials, and expanding customer base are anticipated to fuel market growth. During COVID-19, clinical laboratories experienced high demand for COVID-19 tests. Clinical data management systems assisted these laboratories to seamlessly manage the huge influx of specimens daily. Technological advancements such as electronic data capture and Wi-Fi connectivity are projected to drive the market in the forthcoming years.

As the demand for tracking and analyzing clinical data increases, the need for effective clinical solutions rises. Unmet needs to manage efficient clinical development processes are poised to boost market growth over the forecast period. Moreover, digital transformation in the field of clinical trials and preference for data-centric approaches are providing a tremendous push to the market. Demand for integrated clinical IT solutions is increasing due to the massive volume of data generated during clinical development processes. eClinical solutions offer a single source of information that helps optimize the cost by eliminating redundant data entry and by reducing on-site verification and source data verification. Rising awareness regarding these advantages is projected to propel the market.

Increasing adoption of eClinical workflows in trials offers enormous potential in clinical development processes. These solutions can facilitate decision-making in each stage of development. It helps reduce cost and time between the development phase by utilizing seamless designs and identifying failing compounds. It offers rapid access to data and patient safety information, which helps make quick decisions. Market players engage in new product development and strategic alliances including partnership, agreement, promotional activities, etc. to keep market rivalry high. In August 2023, Sitero acquired Clarios eClinical technology suite to enhance clinical trial delivery. This acquisition demonstrates Sitero's dedication to remain at the forefront of innovation and offering its clients the best possible support and services.

eClinical Solutions Market Report Highlights:

  • Based on product, the CTMS segment led the market in 2024 and accounted for a revenue share of around 20.2% owing to benefits such as centralized end-to-end management of clinical trial activities, elimination of reliance on manual processes, real-time status tracking, and maintenance of multiple databases, which cumulatively improve the overall efficiency of clinical trials
  • Web and cloud-based systems are anticipated to exhibit an exponential CAGR during the forecast period owing to integrated features such as flexibility, high accessibility, negligible handling costs, and easy data backup. Real-time data is available through these systems, which enables users to take quick decisions and provide high-quality information for risk-based monitoring
  • Based on the development phase, the phase III segment held the largest market share of 53.3% in 2024. Phase I segment is expected to grow at the fastest CAGR over the forecast period
  • Based on end-use, the CRO segment held the largest revenue share in 2024. The segment is projected to rise at a remarkable CAGR during the forecast period owing to the growing inclination of pharmaceutical companies to reduce overall expenditure.

Table of Contents

Chapter 1 eClinical Solutions Market: Research Methodology & Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 eClinical Solutions Market Segment Scope
    • 1.1.2 Regional Scope
    • 1.1.3 Estimates & Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased database:
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary sources
    • 1.3.4 Primary Research:
    • 1.3.5 Details of Primary Research
      • 1.3.5.1 Region-specific eClinical solutions market data for primary interviews
        • 1.3.5.1.1 North America
        • 1.3.5.1.2 Europe
        • 1.3.5.1.3 Asia Pacific
        • 1.3.5.1.4 Central & South America
        • 1.3.5.1.5 MEA
  • 1.4 Information or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 eClinical solutions market
      • 1.6.1.1 Consensus-based Estimates & forecasting
        • 1.6.1.1.1 eClinical solutions market - Commodity Flow Analysis
          • 1.6.1.1.1.1 Commodity Flow Analysis level: eConsent in the healthcare market
          • 1.6.1.1.1.2 Country-level assumptions
      • 1.6.1.2 Sub-segment level assumptions
      • 1.6.1.3 Total addressable market analysis (Model 2)
    • 1.6.2 Pharma HUB and patient access support service market
      • 1.6.2.1 Pharma HUB and patient access support service market: Commodity Flow Analysis
  • 1.7 List of Secondary Sources
  • 1.8 Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective 1
    • 1.9.2 Objective 2
    • 1.9.3 Objective 3
  • 1.10 Market Definitions

Chapter 2 eClinical Solutions Market: Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook
    • 2.2.1 Product Segment Outlook
    • 2.2.2 Development Phases & Delivery Mode Segment Outlook
    • 2.2.3 End Use Segment Outlook
    • 2.2.4 Competitive outlook

Chapter 3 eClinical Solutions Market: Variables, Trends & Scope

  • 3.1 Ancillary Market Analysis
    • 3.1.1 eConsent Market
    • 3.1.2 Electronic Clinical Outcome Assessment Solutions Market
    • 3.1.3 Clinical Trials Management System Market
  • 3.2 Pricing Analysis
    • 3.2.1 By product
      • 3.2.1.1 eCOA
      • 3.2.1.2 EDC & CDMS
      • 3.2.1.3 Clinical Analytics Platforms
      • 3.2.1.4 Clinical data integration platforms
      • 3.2.1.5 Safety solutions
      • 3.2.1.6 CTMS
      • 3.2.1.7 RTSM
      • 3.2.1.8 eTMF
    • 3.2.2 By delivery mode
    • 3.2.3 By development phase
  • 3.3 User/Buyer Perception Analysis
    • 3.3.1 Market influencer analysis
      • 3.3.1.1 Regulatory Requirements
      • 3.3.1.2 Technological Developments
      • 3.3.1.3 Product Differentiation
      • 3.3.1.4 Demand from Consumers
  • 3.4 Technology Overview
    • 3.4.1 eClinical solutions changing technology & adoption
  • 3.5 Regulatory Overview
    • 3.5.1 Regulatory Landscape
      • 3.5.1.1 List of regulations, by country
  • 3.6 Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Increasing externalization of clinical trial studies by large pharmaceutical and biopharmaceutical companies
      • 3.6.1.2 Advantages of eClinical solutions
      • 3.6.1.3 Presence of strong range of products in pipeline
      • 3.6.1.4 Increased adoption of eConsent in clinical trials
        • 3.6.1.4.1 eConsent is becoming increasingly accepted and adopted in various industries, particularly in healthcare and clinical trials.
        • 3.6.1.4.2 Advancements in mobile technologies are poised to revolutionize the processes of designing, delivering, and managing informed consent
        • 3.6.1.4.3 The implementation of eConsent in clinical trials has shown to improve patient comprehension and consequently create better trial subjects.
        • 3.6.1.4.4 The implementation of eConsent is beneficial for clinical trial sites, as it greatly improves the consent process.
        • 3.6.1.4.5 Elderly participants report high satisfaction with eConsent
        • 3.6.1.4.6 econsent enhances version control, remote monitoring, and document management.
      • 3.6.1.5 Increased strategic acquisitions and partnerships deals
      • 3.6.1.6 Integration of econsent with other eclinical solutions
      • 3.6.1.7 Market Drivers - Key Insights from Signant Health Survey
    • 3.6.2 Market Restraints Analysis
      • 3.6.2.1 Scarcity of skilled research professionals
      • 3.6.2.2 Lack of recognition
      • 3.6.2.3 Authority Concerns And Its Related Solutions
        • 3.6.2.3.1 Protection Of Patient Data
        • 3.6.2.3.2 Sharing Electronic Consent Data
        • 3.6.2.3.3 Regional And Local Data Privacy Laws
        • 3.6.2.3.4 Site Burden
        • 3.6.2.3.5 Trial Participant Verification
        • 3.6.2.3.6 Responsibilities of the Investigator as the Process Owner of the Informed Consent Process
    • 3.6.3 Market Challenge Analysis
      • 3.6.3.1 Market-related barriers
        • 3.6.3.1.1 Lack of education and communication
        • 3.6.3.1.2 Lack of lean processes and operations
      • 3.6.3.2 Market Challenges - Key Insights from Signant Health Survey
  • 3.7 Industry Analysis - Porter's
  • 3.8 eClinical Solutions Market - SWOT Analysis, by Factor (Political & Legal, Economic, Social and Technological)
  • 3.9 COVID-19 Impact Analysis
    • 3.9.1 Case Study - eConsent implementation during COVid -19 pandemic
    • 3.9.2 Developments & Strategic Outcomes
    • 3.9.3 Strategies implemented by companies
      • 3.9.3.1 Oracle
      • 3.9.3.2 Calyx
      • 3.9.3.3 Datatrak International, Inc.
      • 3.9.3.4 Medidata Solution, Inc.
      • 3.9.3.5 IBM
      • 3.9.3.6 eClinical Solutions
      • 3.9.3.7 Veeva Systems
      • 3.9.3.8 Elsevier
      • 3.9.3.9 IQVIA
      • 3.9.3.10 Pharmaceutical Product Development (PPD)
      • 3.9.3.11 ICON, plc
      • 3.9.3.12 PRA Health Sciences

Chapter 4 eClinical Solutions Market: Product Analysis

  • 4.1 Product Business Analysis
    • 4.1.1 Electronic data capture (EDC) & clinical data management systems (CDMS)
      • 4.1.1.1 EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.1.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.1.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.2 Clinical trial management systems (CTMS)
      • 4.1.2.1 CTMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.2.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.2.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.3 Clinical analytics platform
      • 4.1.3.1 Clinical analytics platform market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.3.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.3.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.4 Electronic clinical outcome assessment (ECOA)
      • 4.1.4.1 Electronic clinical outcome assessment (ECOA) market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.4.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.4.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.5 Clinical data integration platform
      • 4.1.5.1 Clinical data integration platform market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.5.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.5.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.6 Safety solutions
      • 4.1.6.1 Safety solutions market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.6.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.6.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.7 Randomization and trial supply management (RTSM)
      • 4.1.7.1 RTSM market estimates and forecasts, 2018 - 2030 (USD Million)
      • 4.1.7.1 1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.7.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.8 Electronic Trial Master File (eTMF)
      • 4.1.8.1 eTMF market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.8.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.8.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
    • 4.1.9 eConsent
      • 4.1.9.1 eConsent market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.9.1.1 Traditional EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)
        • 4.1.9.1.2 AI-Enhanced EDC & CDMS market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 5 eClinical Solutions Market: Delivery Mode Analysis

  • 5.1 Delivery Mode Business Analysis
    • 5.1.1 Cloud- and Web-based
      • 5.1.1.1 Cloud and web-based market estimates and forecasts, 2018 - 2030 (USD Million)
    • 5.1.2 On-Premise
      • 5.1.2.1 On-Premise market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 6 eClinical Solutions Market: Development Phase Analysis

  • 6.1 Development Phase Business Analysis
    • 6.1.1 Phase I
      • 6.1.1.1 Phase I market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.1.2 Phase II
      • 6.1.2.1 Phase II market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.1.3 Phase III
      • 6.1.3.1 Phase III market estimates and forecasts, 2018 - 2030 (USD Million)
    • 6.1.4 Phase IV
      • 6.1.4.1 Phase IV market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 7 eClinical Solutions Market: End Use Analysis

  • 7.1 End Use Business Analysis
    • 7.1.1 Hospitals/healthcare providers
      • 7.1.1.1 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.2 Contract Research Organizations (CROs)
      • 7.1.2.1 CROs market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.3 Academic institutes
      • 7.1.3.1 Academic institutes market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.4 Pharma & biotech organizations
      • 7.1.4.1 Pharma & biotech organizations market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.1.5 Medical device manufacturers
      • 7.1.5.1 Medical device manufacturers market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8 eClinical Solutions Market: Regional Market Analysis, By Product, By Delivery Mode, By Development Phase, and By End Use, 2018 - 2030 (USD Million)

  • 8.1 Regional Market Share Analysis, 2024 & 2030
  • 8.2 Regional Market Snapshot
  • 8.3 North America
    • 8.3.1 North America eClinical solutions market estimates and forecasts by countries, 2018 - 2030 (USD Million)
    • 8.3.2 U.S.
      • 8.3.2.1 Key Country Dynamics
      • 8.3.2.2 Regulatory framework
      • 8.3.2.3 U.S. eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.3 Canada
      • 8.3.3.1 Key Country Dynamics
      • 8.3.3.2 Regulatory framework
      • 8.3.3.3 Canada eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.3.4 Mexico
      • 8.3.4.1 Key Country Dynamics
      • 8.3.4.2 Regulatory framework
      • 8.3.4.3 Mexico eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.4 Europe
    • 8.4.1 Europe eClinical solutions market estimates and forecasts by countries, 2018 - 2030 (USD Million)
    • 8.4.2 UK
      • 8.4.2.1 Key Country Dynamics
      • 8.4.2.2 Regulatory framework
      • 8.4.2.3 UK eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.3 Germany
      • 8.4.3.1 Key Country Dynamics
      • 8.4.3.2 Regulatory framework
      • 8.4.3.3 Germany eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.4 France
      • 8.4.4.1 Key Country Dynamics
      • 8.4.4.2 Regulatory framework
      • 8.4.4.3 France eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.5 Italy
      • 8.4.5.1 Key Country Dynamics
      • 8.4.5.2 Regulatory framework
      • 8.4.5.3 Italy eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.6 Spain
      • 8.4.6.1 Key Country Dynamics
      • 8.4.6.2 Regulatory framework
      • 8.4.6.3 Spain eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.7 Netherlands
      • 8.4.7.1 Key Country Dynamics
      • 8.4.7.2 Regulatory framework
      • 8.4.7.3 Netherlands eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.8 Denmark
      • 8.4.8.1 Key Country Dynamics
      • 8.4.8.2 Regulatory framework
      • 8.4.8.3 Denmark eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.9 Sweden
      • 8.4.9.1 Key Country Dynamics
      • 8.4.9.2 Regulatory framework
      • 8.4.9.3 Sweden eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.4.10 Norway
      • 8.4.8.1 NORWAY - Case Study:-
      • 8.4.8.2 Key Country Dynamics
      • 8.4.8.3 Regulatory framework
      • 8.4.8.4 Norway eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.5 Asia Pacific
    • 8.5.1 Asia Pacific eClinical solutions market estimates and forecasts,2018 - 2030 (USD Million)
    • 8.5.2 Japan
      • 8.5.2.1 Key Country Dynamics
      • 8.5.2.2 Regulatory framework
      • 8.5.2.3 Japan eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.3 China
      • 8.5.3.1 Key Country Dynamics
      • 8.5.3.2 Regulatory framework
      • 8.5.3.3 China eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.4 India
      • 8.5.4.1 Key Country Dynamics
      • 8.5.4.2 Regulatory framework
      • 8.5.4.3 India eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.5 Australia
      • 8.5.5.1 Key Country Dynamics
      • 8.5.5.2 Regulatory framework
      • 8.5.5.3 Australia eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.6 South Korea
      • 8.5.6.1 Key Country Dynamics
      • 8.5.6.2 Regulatory framework
      • 8.5.6.3 South Korea eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.7 New Zealand
      • 8.5.7.1 Key Country Dynamics
      • 8.5.7.2 Regulatory framework
      • 8.5.7.3 New Zealand eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.8 Taiwan
      • 8.5.8.1 Key Country Dynamics
      • 8.5.8.2 Regulatory framework
      • 8.5.8.3 Taiwan eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.9 Hong kong
      • 8.5.9.1 Key Country Dynamics
      • 8.5.9.2 Regulatory framework
      • 8.5.9.3 Hong kong eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.10 Singapore
      • 8.5.8.1 Key Country Dynamics
      • 8.5.8.2 Regulatory framework
      • 8.5.8.3 Singapore eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.11 Thailand
      • 8.5.11.1 Key Country Dynamics
      • 8.5.11.2 Regulatory framework
      • 8.5.11.3 Thailand eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.5.12 Vietnam
      • 8.5.12.1 Key Country Dynamics
      • 8.5.12.2 Regulatory framework
      • 8.5.12.3 Vietnam eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.6 Central & South America
    • 8.6.1 Central & South America eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.2 Brazil
      • 8.6.2.1 Key Country Dynamics
      • 8.6.2.2 Regulatory framework
      • 8.6.2.3 Brazil eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.3 Argentina
      • 8.6.3.1 Key Country Dynamics
      • 8.6.3.2 Regulatory framework
      • 8.6.3.3 Argentina eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.6.4 Chile
      • 8.6.4.1 Key Country Dynamics
      • 8.6.4.2 Regulatory framework
      • 8.6.4.3 Chile eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
  • 8.7 MEA
    • 8.7.1 MEA eClinical solutions market estimates and forecasts by countries, 2018 - 2030 (USD Million)
    • 8.7.2 South Africa
      • 8.7.2.1 Key Country Dynamics
      • 8.7.2.2 Regulatory framework
      • 8.7.2.3 South Africa eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.3 Saudi Arabia
      • 8.7.3.1 Key Country Dynamics
      • 8.7.3.2 Regulatory framework
      • 8.7.3.3 Saudi Arabia eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.4 UAE
      • 8.7.4.1 Key Country Dynamics
      • 8.7.4.2 Regulatory framework
      • 8.7.4.3 UAE eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.5 Qatar
      • 8.7.5.1 Key Country Dynamics
      • 8.7.5.2 Regulatory framework
      • 8.7.5.3 QATAR eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)
    • 8.7.6 Egypt
      • 8.7.6.1 Key Country Dynamics
      • 8.7.6.2 Regulatory framework
      • 8.7.6.3 EGYPT eClinical solutions market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 9 eClinical Solutions Market: Competitive Landscape

  • 9.1 Participant Overview
  • 9.2 Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Datatrak International, Inc.
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial performance
      • 9.5.1.3. Products & Services benchmarking
      • 9.5.1.4. Strategic initiatives
    • 9.5.2. Oracle
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial performance
      • 9.5.2.3. Products & Services benchmarking
      • 9.5.2.4. Strategic initiatives
    • 9.5.3. Parexel International Corporation
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial performance
      • 9.5.3.3. Products & Services benchmarking
      • 9.5.3.4. Strategic initiatives
    • 9.5.4. Dassault Systemes
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial performance
      • 9.5.4.3. Products & Services benchmarking
      • 9.5.4.4. Strategic initiatives
    • 9.5.5. Bioclinica
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial performance
      • 9.5.5.3. Products & Services benchmarking
      • 9.5.5.4. Strategic initiatives
    • 9.5.6. CRF Health
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial performance
      • 9.5.6.3. Products & Services benchmarking
      • 9.5.6.4. Strategic initiatives
    • 9.5.7. ERT Clinical
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial performance
      • 9.5.7.3. Products & Services benchmarking
      • 9.5.7.4. Strategic initiatives
    • 9.5.8. eClinicalWorks
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial performance
      • 9.5.8.3. Products & Services benchmarking
      • 9.5.8.4. Strategic initiatives
    • 9.5.9. IBM Watson Health
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial performance
      • 9.5.9.3. Products & Services benchmarking
      • 9.5.9.4. Strategic initiatives
    • 9.5.10. Anju Life Sciences Software
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial performance
      • 9.5.10.3. Products & Services benchmarking
      • 9.5.10.4. Strategic initiatives
    • 9.5.11. eClinical Solutions
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial performance
      • 9.5.11.3. Products & Services benchmarking
      • 9.5.11.4. Strategic initiatives
    • 9.5.12. Maxisit
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial performance
      • 9.5.12.3. Products & Services benchmarking
      • 9.5.12.4. Strategic initiatives
    • 9.5.13. IQVIA
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial performance
      • 9.5.13.3. Products & Services benchmarking
      • 9.5.13.4. Strategic initiatives
    • 9.5.14. Castor
      • 9.5.14.1. Overview
      • 9.5.14.2. Financial performance
      • 9.5.14.3. Products & Services benchmarking
      • 9.5.14.4. Strategic initiatives
    • 9.5.15. Veeva Systems
      • 9.5.15.1. Overview
      • 9.5.15.2. Financial performance
      • 9.5.15.3. Products & Services benchmarking
      • 9.5.15.4. Strategic initiatives
    • 9.5.16. RealTime Software Solutions, LLC
      • 9.5.16.1. Overview
      • 9.5.16.2. Financial performance
      • 9.5.16.3. Products & Services benchmarking
      • 9.5.16.4. Strategic initiatives
    • 9.5.17. Medidata Solution, Inc
      • 9.5.17.1. Overview
      • 9.5.17.2. Financial performance
      • 9.5.17.3. Products & Services benchmarking
      • 9.5.17.4. Strategic initiatives
    • 9.5.18. ICON, plc
      • 9.5.18.1. Overview
      • 9.5.18.2. Financial performance
      • 9.5.18.3. Products & Services benchmarking
      • 9.5.18.4. Strategic initiatives
    • 9.5.19. Deep 6 AI
      • 9.5.19.1. Overview
      • 9.5.19.2. Financial Performance
      • 9.5.19.3. Products & Services Benchmarking
      • 9.5.19.4. Strategic Initiatives (Acquired by Tempus on March 12, 2025)
    • 9.5.20. Phesi
      • 9.5.20.1. Overview
      • 9.5.20.2. Financial Performance
      • 9.5.20.3. Products & Services Benchmarking
      • 9.5.20.4. Strategic Initiatives
    • 9.5.21. Curebase
      • 9.5.21.1. Overview
      • 9.5.21.2. Financial Performance
      • 9.5.21.3. Products & Services Benchmarking
      • 9.5.21.4. Strategic Initiatives
    • 9.5.22. Saama
      • 9.5.22.1. Overview
      • 9.5.22.2. Financial Performance
      • 9.5.22.3. Products & Services Benchmarking
      • 9.5.22.4. Strategic Initiatives
    • 9.5.23. Suvoda LLC
      • 9.5.23.1. Overview
      • 9.5.23.2. Financial Performance
      • 9.5.23.3. Products & Services Benchmarking
      • 9.5.23.4. Strategic Initiatives (Merged with Greenphire in April 2025)
    • 9.5.24. Cencora Pharmalex
      • 9.5.24.1. Overview
      • 9.5.24.2. Financial Performance
      • 9.5.24.3. Products & Services Benchmarking
      • 9.5.24.4. Strategic Initiatives (Acquired by AmerisourceBergen Corporation in January 2023)
    • 9.5.25. Clinion
      • 9.5.25.1. Overview
      • 9.5.25.2. Financial Performance
      • 9.5.25.3. Products & Services Benchmarking
      • 9.5.25.4. Strategic Initiatives
    • 9.5.26. Jeeva Clinical Trials Inc.
      • 9.5.26.1. Overview
      • 9.5.26.2. Financial Performance
      • 9.5.26.3. Products & Services Benchmarking
      • 9.5.26.4. Strategic Initiatives
    • 9.5.27. Trial Interactive by TransPerfect
      • 9.5.27.1. Overview
      • 9.5.27.2. Financial Performance
      • 9.5.27.3. Products & Services Benchmarking
      • 9.5.27.4. Strategic Initiatives

Chapter 10 KOL Recommendations/Conclusion

Chapter 11 Survey insights/Use cases

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제